Comparison

PKLR (Pyruvate Kinase Isozymes R/L, Pyruvate Kinase 1, R-type/L-type Pyruvate Kinase, Red Cell/Liver Pyruvate Kinase, PK1, PKL)

Item no. USB-P9545-03D
Manufacturer United States Biological
Amount 100 ul
Category
Type Antibody Polyclonal
Format Lyophilized
Applications WB, ELISA
Specific against Mouse (Murine, Mus musculus)
Host Rabbit
Isotype IgG
Purity Purified by immunoaffinity chromatography.
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Type
Pab
Manufacturer - Category
Antibodies / Antibodies-Enzymes
Shipping Temperature
Blue Ice
Storage Conditions
-20°C
Grade
Affinity Purified
Form
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
EU Commodity Code
30021010
Immunogen
Synthetic peptide corresponding to 19aa peptide of mouse PKLR (accession #P53657), N-terminal (KLH).
Specificity
Recognizes mouse PKLR.
Description
Pyruvate kinase is an enzyme involved in glycolysis. It catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate to ADP, yielding a pyruvate molecule. There are 4 isozymes of pyruvate kinase in mammals: L, R, M1 and M2. L type is major isozyme in the liver, R is found in red cells, M1 is the main form in muscle, heart and brain, and M2 is found in early fetal tissues

Highly expressed in liver and RBCs. The PKLR gene codes for both the liver and red blood cell isozymes. The PKM2 gene, located on chromosome 15q22, encodes 2 muscle-specific isoforms, M1 and M2. The PK enzyme functions as a homotetramer. Studies with the rat enzyme suggested that the red cell type is longer than the liver type in the 5-prime terminal end, but the rest of the sequence is very similar. deduced protein sequence was similar to that of L-type PK, with an additional 31aa at the N-terminus. Additional studies demonstrated that the difference between the L- and R-type pyruvate kinases is due to tissue-specific mRNAs, likely resulting from differential processing of a common nuclear RNA precursor. Defects in this enzyme, due to gene mutations or genetic variations, are the common cause of chronic hereditary nonspherocytic hemolytic anemia (CNSHA or HNSHA).

Applications:
Suitable for use in Western Blot and ELISA. Other applications not tested.

Recommended Dilution:
Western Blot: 1-10ug/ml (chemiluminescence)
ELISA: 1:100, 000 (50-100ng control peptide/well.)
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ul
Available: In stock
available

Delivery expected until 11/27/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close